

Form 51-102F3
Material Change Report

1. Name and Address of Company

Enttheon Biomedical Corp. (formerly, MPV Exploration Inc.)
Suite 720 - 999 W Broadway Street
Vancouver, BC
V5Z 1K5
(the "Company")

2. Dates of Material Change(s)

November 11, 2021

3. News Release(s)

News release was issued on November 11, 2021 and disseminated via Baystreet News and Stockwatch pursuant to section 7.1 of National Instrument 51-102.

4. Summaries of Material Changes

The Company announces granted 1,150,000 restricted share units (the "RSUs") to consultants of the Company. The RSUs are valid for a three-year term and are governed by the Company's RSU Plan, approved by the Company's directors on October 20, 2021 and subject to shareholder approval at the upcoming Annual General Meeting on November 19, 2021.

5. Full Description of Material Changes

News Release dated November 11, 2021– See Schedule "A".

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information

No information has been omitted.

8. Executive Officer

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

9. Date of Report

This report is dated November 12, 2021

SCHEDULE "A"
to the Material Change Report dated November 12, 2021

Entheon Biomedical Grants RSUs

Vancouver, British Columbia--(November 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced today that the Company has granted 1,150,000 restricted share units (the "RSUs") to consultants of the Company. The RSUs are valid for a three-year term and are governed by the Company's RSU Plan, approved by the Company's directors on October 20, 2021 and subject to shareholder approval at the upcoming Annual General Meeting on November 19, 2021.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products ("**DMT Products**") for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

For more information, please contact the Company at:

Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
joe@entheonbiomedical.com
<https://entheonbiomedical.com/>

For media inquiries, please contact Elizabeth Glassen of BlueSky Communications at:

BlueSky Communications
Elizabeth Glassen, Account Manager
Telephone: +1 (647) 309-0141
eglassen@blueskycommunications.com

Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.